160 related articles for article (PubMed ID: 26564800)
1. Locus-specific gene repositioning in prostate cancer.
Leshner M; Devine M; Roloff GW; True LD; Misteli T; Meaburn KJ
Mol Biol Cell; 2016 Jan; 27(2):236-46. PubMed ID: 26564800
[TBL] [Abstract][Full Text] [Related]
2. Tissue-of-origin-specific gene repositioning in breast and prostate cancer.
Meaburn KJ; Agunloye O; Devine M; Leshner M; Roloff GW; True LD; Misteli T
Histochem Cell Biol; 2016 Apr; 145(4):433-46. PubMed ID: 26791532
[TBL] [Abstract][Full Text] [Related]
3. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.
Paulo P; Barros-Silva JD; Ribeiro FR; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
Genes Chromosomes Cancer; 2012 Mar; 51(3):240-9. PubMed ID: 22081504
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions.
Latini JM; Rieger-Christ KM; Wang DS; Silverman ML; Libertino JA; Summerhayes IC
J Urol; 2001 Nov; 166(5):1931-6. PubMed ID: 11586263
[TBL] [Abstract][Full Text] [Related]
5. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
Alers JC; Krijtenburg PJ; Rosenberg C; Hop WC; Verkerk AM; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
Lab Invest; 1997 Nov; 77(5):437-48. PubMed ID: 9389787
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.
Dos Reis ST; Pontes J; Villanova FE; Borra PM; Antunes AA; Dall'oglio MF; Srougi M; Leite KR
J Urol; 2009 May; 181(5):2320-5. PubMed ID: 19303106
[TBL] [Abstract][Full Text] [Related]
7. Localization of genetic elements of intact and derivative chromosome 11 and 22 territories in nuclei of Ewing sarcoma cells.
Taslerová R; Kozubek S; Bártová E; Gajdusková P; Kodet R; Kozubek M
J Struct Biol; 2006 Sep; 155(3):493-504. PubMed ID: 16837212
[TBL] [Abstract][Full Text] [Related]
8. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
9. Locus-specific and activity-independent gene repositioning during early tumorigenesis.
Meaburn KJ; Misteli T
J Cell Biol; 2008 Jan; 180(1):39-50. PubMed ID: 18195100
[TBL] [Abstract][Full Text] [Related]
10. Spatial genome organization.
Parada LA; Sotiriou S; Misteli T
Exp Cell Res; 2004 May; 296(1):64-70. PubMed ID: 15120995
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Stamey TA; Warrington JA; Caldwell MC; Chen Z; Fan Z; Mahadevappa M; McNeal JE; Nolley R; Zhang Z
J Urol; 2001 Dec; 166(6):2171-7. PubMed ID: 11696729
[TBL] [Abstract][Full Text] [Related]
12. Golgi phosphoprotein 3 regulates metastasis of prostate cancer via matrix metalloproteinase 9.
Li W; Qi K; Wang Z; Gu M; Chen G; Guo F; Wang Z
Int J Clin Exp Pathol; 2015; 8(4):3691-700. PubMed ID: 26097550
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness.
Stanford JL; McDonnell SK; Friedrichsen DM; Carlson EE; Kolb S; Deutsch K; Janer M; Hood L; Ostrander EA; Schaid DJ
Prostate; 2006 Feb; 66(3):317-25. PubMed ID: 16245279
[TBL] [Abstract][Full Text] [Related]
14. A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporadic prostate cancer.
Nam RK; Zhang WW; Loblaw DA; Klotz LH; Trachtenberg J; Jewett MA; Stanimirovic A; Davies TO; Toi A; Venkateswaran V; Sugar L; Siminovitch KA; Narod SA
Prostate Cancer Prostatic Dis; 2008; 11(3):241-6. PubMed ID: 17876339
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetics of prostate cancer.
Isaacs WB
Cancer Surv; 1995; 25():357-79. PubMed ID: 8718527
[TBL] [Abstract][Full Text] [Related]
16. c-met proto-oncogene expression in benign and malignant human prostate tissues.
Pisters LL; Troncoso P; Zhau HE; Li W; von Eschenbach AC; Chung LW
J Urol; 1995 Jul; 154(1):293-8. PubMed ID: 7539865
[TBL] [Abstract][Full Text] [Related]
17. Expression and nuclear localization of ErbB3 in prostate cancer.
Koumakpayi IH; Diallo JS; Le Page C; Lessard L; Gleave M; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2006 May; 12(9):2730-7. PubMed ID: 16675564
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis of genomic aberrations associated with prostate cancer progression.
Kim JH; Dhanasekaran SM; Mehra R; Tomlins SA; Gu W; Yu J; Kumar-Sinha C; Cao X; Dash A; Wang L; Ghosh D; Shedden K; Montie JE; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2007 Sep; 67(17):8229-39. PubMed ID: 17804737
[TBL] [Abstract][Full Text] [Related]
19. Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q.
Yin Z; Babaian RJ; Troncoso P; Strom SS; Spitz MR; Caudell JJ; Stein JD; Kagan J
Oncogene; 2001 Apr; 20(18):2273-80. PubMed ID: 11402322
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping.
Cher ML; Bova GS; Moore DH; Small EJ; Carroll PR; Pin SS; Epstein JI; Isaacs WB; Jensen RH
Cancer Res; 1996 Jul; 56(13):3091-102. PubMed ID: 8674067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
